MF59™ as a vaccine adjuvant: A review of safety and immunogenicity

Expert Review of Vaccines

Volumn 9, Issue 10, 2010, Pages 1135-1141

  El Sahly, Hana ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BCM MS280 ^*  (United States)

Author keywords

adjuvant; immunogenicity; MF59; safety; squalene; vaccine

Indexed keywords

INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; IMMUNOLOGICAL ADJUVANT; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ERYTHEMA; HEADACHE; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; MALAISE; MYALGIA; NONHUMAN; PAIN; PRIORITY JOURNAL; REVIEW; VIRUS STRAIN; AGED; BLOOD; CHILD; CLINICAL TRIAL (TOPIC); FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFANT; INFLUENZA VIRUS A; INFLUENZA VIRUS B; PRESCHOOL CHILD; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; POLYSORBATES; SQUALENE;

EID: 77957930898     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.111     Document Type: Review

References (59)

1. Stokes J Jr, Weibel RE, Drake ME, Woodhour, AF, Hilleman MR. New metabolizable immunologic adjuvant for human use. 3. Efficacy and toxicity studies in man. N. Engl. J. Med. 271, 479-487 (1964).
2. Weibel RE, Woodhour AF, Stokes J Jr, Metzgar DP, Hilleman MR. New metabolizable immunologic adjuvant for human use. 5. Evaluation of highly purified influenza-virus in adjuvant 65. N. Engl. J. Med. 276, 78-84 (1967).
3. Hilleman MR, Woodhour A, Friedman A, Weibel RE, Stokes J Jr. The clinical application of adjuvant 65. Ann. Allergy 30, 152-158 (1972).
4. Byars NE, Allison AC. Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity. Vaccine 5, 223-228 (1987).
5. Byars NE, Allison AC, Harmon MW, Kendal AP. Enhancement of antibody responses to influenza B virus haemagglutinin by use of a new adjuvant formulation. Vaccine 8, 49-56 (1990).
6. Keitel W, Couch R, Bond N, Adair S, Van Nest G, Dekker C. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11, 909-913 (1993).
7. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13, 1557-1562 (1995).
8. Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: a 10-year perspective. In: Methods in Molecular Medicine, Volume 42: Vaccine Adjuvants: Preparation Methods and Research Protocols. O Hagan DT (Ed.). Humana Press Inc., NJ, USA, 211-228 (2000).
9. Bloch KE. Sterol structure and membrane function. CRC. Crit. Rev. Biochem. 14, 47-92 (1983).
10. Herbert WJ. Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature 210, 747-748 (1966).
11. Dupuis M, McDonald DM, Ott G. Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. Vaccine 18, 434-439 (2000).
12. Dupuis M, Murphy TJ, Higgins D et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 186, 18-27 (1998).
13. Seubert A, Monaci E, Pizza M, O Hagan DT, Wack A. The adjuvants Aluminum Hydroxide and MF59 induce monocyte and granylocytes chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180, 5402-5412 (2008).
14. Mosca F, Tritto E, Muzzi A et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105, 10501-10506 (2008). Interesting paper that evaluates the molecular mechanism of action of MF59.
15. Singh M, O Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081 (1999).
16. + T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106, 3877-3882 (2009).
17. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19, 2673-2680 (2001).
18. Ruf BR, Colberg K, Frick M, Preusche A. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly. Infection 32, 191-198 (2004).
19. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 21, 1268-1274 (2003).
20. De Donato S, Granoff D, Minutello M et al. Safety and Immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 17, 3094-3101 (1999).
21. Frey S, Poland G, Percell S, Podda A. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 21, 4234-4237 (2003).
22. Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59- adjuvanted influenza vaccine (Fluad) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27, 6291-6295 (2009).
23. Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/duck/ Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357, 1937-1943 (2001).
24. Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 in adults. J. Infect. Dis. 197, 667-675 (2008).
25. Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF-59 adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 43, 1135-1142 (2006).
26. Clark TW, Pareek M, Hoschler K et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361, 2424-2435 (2009).
27. Del Giudice G, Hilbert K, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24, 3063-3065 (2006).
28. Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/duck/ Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 191, 1210-1215 (2005).
29. Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106, 7962-7967 (2009).
30. Camilloni B, Neri M, Iorio AM. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59- adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Vaccine 27, 4099-4103 (2009).
31. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 35, 337-344 (2006).
32. Puig-Barberà J, Diez-Domingo J, Pérez Hoyos S, Belenguer Varea A, González Vidal D. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23, 283-289 (2004).
33. Puig-Barberà J, Díez-Domingo J, Varea AB et al. Effectiveness of MF59- adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25, 7313-7321 (2007).
34. Kong WP, Xu L, Stadler K et al. Modulation of the immune response to the severe acute respiratory sundrome spike glycoprotein by gene-based and inactivated virus immunization. J. Virol. 79, 13915-13923 (2005).
35. Vajdy M, Selby M, Medina-Selby A et al. Hepatitis C virus polyprotein vaccine formulations capabale of inducing broad antibody and cellular immune responses. J. Gen. Virol. 87, 2253-2262 (2006).
36. Giuliani MM, Adu-Bobie J, Comanducci M et al. A universal vaccine for serogroup B meningococcus. Proc. Natl Acad. Sci. USA 103, 10834-10839 (2006).
37. Fukasawa LO, Dias WO, Schenkman RP, Raw I, Tanizaki MM. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitides serogroups B/C in neonatal mice. FEMS Immunol. Med. Microbiol. 41, 205-210 (2004).
38. Steeghs L, Kuipers B, Hamstra HJ, Kersten G, van Alphen L, van der Ley P. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect. Immun. 67, 4988-4993 (1999).
39. Granoff DM, McHugh YE, Raff HV, Mokatrin AS, Van Nest GA. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseriameningitidis group C oligosaccharide- CRM197 conjugate vaccine. Infect. Immun. 65, 1710-1715 (1997).
40. Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine 24, 766-775 (2006).
41. Pass RF, Duliegé AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis. 180, 970-975 (1999).
42. Stowers AW, Cioce V, Shimp RL. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect. Immun. 69, 1536-1546 (2001).
43. Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. 93, 284-292 (2001).
44. Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant.Vaccine 17, 2769-2778 (1999).
45. Lewis DJ, Eiden JE, Goilav C, Langenberg AG, Suggett F, Griffin GE. Rapid and frequent induction of protective immunity exceeding UK recommendations for healthcare settings by MF59-adjuvated hepatitis B vaccine. Commun. Dis. Public Health 6, 320-324 (2003).
46. Verschoor EJ, Mooij P, Oostermeijer H et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOMformulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol. 73, 3292-3300 (1999).
47. O Hagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine 17, 2229-2236 (1999).
48. Singh M, Carlson JR, Briones M et al. A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16, 1822-1827 (1998).
49. Ugozzoli M, O Hagan DT, Ott GS. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 93, 563-571 (1998).
50. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59- adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27, 6959-6965 (2009).
51. Schultze V, D Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59™ adjuvant. Vaccine 26, 3209-3222 (2008).
52. Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy - a retrospective analysis. Vaccine 28, 1877-1880 (2010).
53. Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Adjuvants and autoimmunity. Lupus 18, 1217-1225 (2009).
54. Asa PB, Cao Y, Garry RF. Antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68, 55-64 (2000).
55. Alving CR, Grabenstein JD. Re: antibodies to squalene in Gulf War syndrome. Exp. Mol. Pathol. 68, 196-198 (2000).
56. Gulf War and Health. Volume 1. Depleted Uranium, Sarin, Pyridostigmine Bromide, Vaccines. Fulco CA, Liverman CT, Sox HC (Eds). Institute of Medicine, National Academy Press, Washington, DC, USA (2000).
57. Matyas GR, Rao M, Pittman PR et al. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. J. Immunol. Methods 286, 47-67 (2004).
58. Del Giudice G, Fragapane E, Bugarini R et al. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin. Vaccine. Immunol. 13, 1010-1013 (2006). Evaluates the presence of antisqualene antibodies pre- and post-vaccination with MF59-adjuvanted and nonadjuvanted influenza vaccines.
59. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360, 1191-1199 (2009).